GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » VolitionRX Ltd (AMEX:VNRX) » Definitions » Cyclically Adjusted Price-to-FCF

VolitionRX (VolitionRX) Cyclically Adjusted Price-to-FCF : (As of May. 16, 2024)


View and export this data going back to 2007. Start your Free Trial

What is VolitionRX Cyclically Adjusted Price-to-FCF?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted Price-to-FCF for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


VolitionRX Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for VolitionRX's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VolitionRX Cyclically Adjusted Price-to-FCF Chart

VolitionRX Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

VolitionRX Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of VolitionRX's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, VolitionRX's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VolitionRX's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, VolitionRX's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where VolitionRX's Cyclically Adjusted Price-to-FCF falls into.



VolitionRX Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

VolitionRX's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, VolitionRX's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.103/131.7762*131.7762
=-0.103

Current CPI (Mar. 2024) = 131.7762.

VolitionRX Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.096 100.560 -0.126
201409 -0.082 100.428 -0.108
201412 -0.069 99.070 -0.092
201503 -0.138 99.621 -0.183
201506 -0.110 100.684 -0.144
201509 -0.130 100.392 -0.171
201512 -0.113 99.792 -0.149
201603 -0.112 100.470 -0.147
201606 -0.102 101.688 -0.132
201609 -0.090 101.861 -0.116
201612 -0.084 101.863 -0.109
201703 -0.136 102.862 -0.174
201706 -0.120 103.349 -0.153
201709 -0.110 104.136 -0.139
201712 -0.150 104.011 -0.190
201803 -0.131 105.290 -0.164
201806 -0.102 106.317 -0.126
201809 -0.142 106.507 -0.176
201812 -0.106 105.998 -0.132
201903 -0.104 107.251 -0.128
201906 -0.075 108.070 -0.091
201909 -0.096 108.329 -0.117
201912 -0.067 108.420 -0.081
202003 -0.125 108.902 -0.151
202006 -0.108 108.767 -0.131
202009 -0.097 109.815 -0.116
202012 -0.082 109.897 -0.098
202103 -0.131 111.754 -0.154
202106 -0.106 114.631 -0.122
202109 -0.094 115.734 -0.107
202112 -0.085 117.630 -0.095
202203 0.065 121.301 0.071
202206 -0.126 125.017 -0.133
202209 -0.127 125.227 -0.134
202212 -0.111 125.222 -0.117
202303 -0.149 127.348 -0.154
202306 -0.114 128.729 -0.117
202309 -0.111 129.860 -0.113
202312 0.077 129.419 0.078
202403 -0.103 131.776 -0.103

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


VolitionRX  (AMEX:VNRX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


VolitionRX Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of VolitionRX's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


VolitionRX (VolitionRX) Business Description

Traded in Other Exchanges
N/A
Address
1489 West Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
VolitionRX Ltd is a United states based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Executives
Eight Corp Ltd 10 percent owner C/O CROWE MORGAN, 8 ST. GEORGE'S STREET, DOUGLAS Y8 IM1 1AH
Salvatore Thomas Butera director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Rodney Gerard Rootsaert director, officer: SECRETARY 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Cameron John Reynolds director, officer: PRESIDENT AND CEO 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Guy Archibald Innes director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Edward Futcher director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Phillip Barnes director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Martin Charles Faulkes director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Mickie Henshall director 1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON NV 89014
Jacob Vincent Micallef officer: Chief Scientific Officer 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Michel Gaetan other: Manager Belgian Volition SPRL 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Jasmine Kway other: CEO-Singapore Volition 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Nicholas Plummer officer: GC - Volition Diagnostics 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Ann-louise Batchelor officer: Group Chief Marketing Officer 1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON NV 89014
Terrell Jason Bradley Md officer: Chief Medical Officer 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014